News, Publications & Insights

Explore the latest news and publications, innovation milestones, and drug-device insights from PARI and our pharmaceutical partners leveraging eFlow® Technology.

PARI Partner Project News

Partner Project News

Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001

PARI Publication

PARI Publication

A Novel Human Factors Approach for a New Platform-Based, Breath-Triggered Nebuliser

Published

January 12, 2022

Category

Publications

Inhaled Medicines: Past, Present, and Future

Inhaled Medicines: Past, Present, and Future

Published

December 30, 2021

Category

Partner News

Polyphor closes merger with EnBiotix and is renamed Spexis

Polyphor closes merger with EnBiotix and is renamed Spexis

Published

December 10, 2021

Category

PARI Publications

eFlow Technology Nebulisers with Digital Therapy Management: The PARI Connect Eco-System.

eFlow Technology Nebulisers with Digital Therapy Management: The PARI Connect Eco-System.

Published

October 7, 2021

Category

Publications

Impact of baseline clinical features on outcomes of nebulized glycopyrrolate therapy in COPD.

Impact of baseline clinical features on outcomes of nebulized glycopyrrolate therapy in COPD.

Published

September 24, 2021

Category

Publications

Deposition of Inhaled Levofloxacin in Cystic Fibrosis Lungs Assessed by Functional Respiratory Imaging.

Deposition of Inhaled Levofloxacin in Cystic Fibrosis Lungs Assessed by Functional Respiratory Imaging.

Contact us

eFlow-partneringpari.com

Two smiling men in a blue circle. The central man wears glasses and a light blue shirt. The man on the left has a beard and a blue patterned shirt.

PARI Business Development Team